AVEO Projected Dividend Yield
AVEO Pharmaceuticals Inc ( NASDAQ : AVEO )AVEO Pharmaceuticals is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines for patients with cancer. Co.'s product candidates include: Tivozanib, which is for the treatment of renal cell carcinoma, hepatocellular carcinoma, immunologically cold tumors and cholangiocarcinoma; Ficlatuzumab, which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor; AV-380, which is a humanized IgG1 monoclonal antibody that targets growth differentiation factor 15; AV-203, which is a humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353, which is a IgG1 monoclonal antibody that targets the Notch 3 pathway. 20 YEAR PERFORMANCE RESULTS |
AVEO Dividend History Detail AVEO Dividend News AVEO Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |